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Is extended preoperative antibiotic prophylaxis
for high-risk patients necessary before
percutaneous nephrolithotomy?
Aaron M. Potretzke1, Alyssa M. Park1, Tyler M. Bauman1, Jeffrey A. Larson1, Joel M. Vetter1, Brian M. Benway2,
Alana C. Desai1
1

Division of Urology, Washington University School of Medicine, Saint Louis, MO, 2Urology Academic Practice, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Purpose: The goal of this study was to compare the rate of systemic inflammatory response syndrome (SIRS) in high-risk patients
undergoing percutaneous nephrolithotomy (PCNL) between patients who received 7, 2, or 0 days of preoperative antibiotics.
Materials and Methods: We retrospectively reviewed a series of consecutive PCNLs performed at our institution. Patients with infected preoperative urine cultures were excluded. High-risk patients were defined as those with a history of previous urinary tract
infection (UTI), hydronephrosis, or stone size ≥2 cm. Patients were treated with 7, 2, or 0 days of preoperative antibiotic prophylaxis
prior to PCNL. All patients received a single preoperative dose of antibiotics within 60 minutes of the start of surgery. Fisher exact
test was used to compare the rate of SIRS by preoperative antibiotic length.
Results: Of the 292 patients identified, 138 (47.3%) had sterile urine and met high-risk criteria, of which 27 (19.6%), 39 (28.3%),
and 72 (52.2%) received 7, 2, and 0 days of preoperative antibiotics, respectively. The 3 groups were similar in age, sex, and duration of surgery (p>0.05). There was no difference in the rate of SIRS between the groups, with 1 of 27 (3.7%), 2 of 39 (5.1%) and 3 of
72 patients (4.2%) meeting criteria in the 7, 2, and 0 days antibiotic groups (p=~1).
Conclusions: Extended preoperative antibiotic prophylaxis was not found to reduce the risk of SIRS after PCNL in our institutional
experience of high-risk patients. For these patients, a single preoperative dose of antibiotics is sufficient.
Keywords: Antibiotic prophylaxis; Hydronephrosis; Percutaneous nephrostomy; Systemic inflammatory response syndrome; Urolithiasis
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION
Urolithiasis is one of the most common urologic condi
tions, and it has recently been estimated that the prevalence
of stones in Americans is 8.8% [1]. In 2000, the United States
spent in excess of 2 billion dollars treating stone disease [2].
Percutaneous nephrolithotomy (PCNL) is widely accepted

as the ideal surgical choice for patients with a large stone
burden and is becoming an increasingly common operation.
In the United States, the number of PCNLs performed
has more than doubled in the last decade, and its use may
continue to increase in future years [3].
Urosepsis is a well-known and potentially life-threate
ning complication following PCNL for staghorn and large
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renal calculi. While the overall incidence of urosepsis in
the reported literature is approximately 1%, the historical
mortality rate of post-PCNL sepsis is as high as 66%–80% [4,5].
More commonly, patients experience less severe symptoms
of infection postoperatively, including fever (21%–74%),
bacteriuria (10%–37%), and bacteremia (20%–35%) [6-8].
Due to the prevalence of infection-related complications
and potential consequences of severe infection after PCNL,
both the American Urological Association (AUA) and
European Association of Urology (EAU) clinical practice
statements have formulated specific recommendations
regarding preoperative antibiotic prophylaxis in this patient
population.
The AUA Best Practice Statement regarding antimicro
bial prophylaxis recommends that all patients undergoing
PCNL receive antibiotic prophylaxis for a duration of
24 hours or less. Similarly, the 2015 guidelines set forth
by the EAU confers a grade “A” recommendation for
the treatment of all stones >2 cm with PCNL [9]. The
EAU guidelines also note that a single preoperative dose
appears to be effective. However, recommendations for
the empiric perioperative antibiotic treatment of specific
populations (e.g., high-risk patients) are not provided. This
is due in large part to a paucity of data in the urological
literature [10,11]. Anecdotally, some urologists may prescribe
extended antibiotics in those deemed to be high-risk for
developing postoperative infection, such as patients with
staghorn calculi or a history of recurrent urinary tract
infection (UTI). We sought to evaluate a cohort of highrisk patients undergoing PCNL and compare the rates of
systemic inflammatory response syndrome (SIRS) in those
who received 7, 2, or 0 days (intraoperative dose only) of
preoperative antibiotics.

MATERIALS AND METHODS
1. Patients

After Institutional Review Board approval (201304085),
data was retrospectively reviewed from a prospectively
maintained database of all patients undergoing PCNL by
2 surgeons at our institution from January 2012 to June
2014. All patients at our institution must have a negative
preoperative urine culture within 7 days of surgery. Those
who had a previous positive urine culture within 30 days
prior to surgery were excluded from analysis. High-risk
criteria were selected based on previous literature which
demonstrated an association between post-PCNL infectious
complications and the following preoperative variables:
(1) presence of hydronephrosis, (2) stone size in greatest
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dimension of ≥2 cm, and (3) history of recurrent UTIs
[12,13]. Patients were considered high-risk for postoperative
infectious complications (e.g., SIRS) if they manifested one of
these variables. The present study included patients with a
history of UTI, which was defined as having symptomatic,
culture-proven bacteriuria. Evaluation of hydronephrosis
and quantification of stone burden were performed by both
the treating urologist and by a fellowship-trained abdominal
radiologist. The etiology of the hydronephrosis (i.e., presence
of a ureteral stone versus ureteropelvic junction obstruction
by a renal pelvic stone) was not distinguished. SIRS criteria
were defined as having 2 or more of the following clinical
parameters simultaneously during the postoperative
hospitalization: (1) temperature ≥38oC or ≤36oC, (2) heart rate
>100 beats/min, (3) respiratory rate >20 breaths/min, and
(4) white blood cell count (WBC) >12,000/µL or <4,000/µL
[12]. Complications were categorized via the Clavien-Dindo
classification system [14].

2. Antibiotics

Formerly, the clinical practice of one author (ACD)
included 7-day oral antibiotic administration preoperatively
for high-risk PCNL patients. Af ter consultation with
infectious disease specialists and pharmacists at our
institution, the practice was changed to 2 days of
preoperative treatment, as 2 days of treatment suffices to
reach therapeutic serum drug levels. The clinical practice of
another author (BMB) includes a single, preoperative dose of
antibiotics within 60 minutes of the start of the operation.
Therefore, 3 groups of patients exist in our institutional
experience: those receiving 7, 2, and 0 days of antibiotics
before PCNL. All patients received a preoperative dose of
antibiotics within 1 hour of the start of the case. Choice
of preoperative, intravenous antibiotic was consistent
with AUA guidelines (1st/2nd generation cephalosporin or
fluoroquinolone as an alternative), with the exception of
patients with a history of resistant organisms. Choice of oral
antibiotic was ciprofloxacin 500 mg twice daily (adjusted
as necessary for renal function), except in the setting of a
previous resistant organism.

3. Surgical technique and postoperative care

The indications for PCNL were based on the composite
of multiple factors, including stone size, configuration,
location, expected (or historical) composition, and patient
preference. An external ureteral catheter was placed
cystoscopically at the beginning of each procedure. Patients
were positioned prone. Energy sources employed f or
lithotripsy included ultrasonic, pneumatic, and holmium
https://doi.org/10.4111/icu.2016.57.6.417

Antibiotics before percutaneous nephrolithotomy
laser. Percutaneous access was established by fellowshiptrained interventional radiologists. Nephrostomy tube and
ureteral stent were placed at the discretion of the urologist.
Routinely, nephrostomy tubes were removed prior to patient
discharge from the hospital, while ureteral stents remained
in place for 1 to 2 weeks postoperatively. Vital signs were
assessed after surgery every 15 minutes for the first hour,
every 30 minutes for the second hour, and every 4 hours
thereafter. WBC counts were checked at the discretion of
the surgeon.

4. Statistical analysis

Fisher exact test was used to compare the rate of SIRS
by preoperative antibiotic length. Chi-square tests and
Kruskal-Wallis tests were used to compare categorical and

numerical demographic variables respectively. All statistics
were done in R version 3.2.0.

RESULTS
A total of 292 patients underwent PCNL during the
study period, of which 138 met inclusion criteria. Twentyseven, 39, and 72 patients were treated with 7, 2, or 0 days
of preoperative antibiotics. There were no signif icant
dif ferences in baseline characteristics, including age,
body mass index, sex, duration of surgery, stone size,
hydronephrosis, and a history of UTI (p>0.05) (Table 1).
The specific signs and overall rates of SIRS for each of the
three groups are shown in Table 2. Although there was no
statistically significant difference in rates of SIRS between

Table 1. Patient clinical and operative data
Variable
Age (y), median (IQR)
BMI (kg/m2), median (IQR)
Stone size (mm), median (IQR)
Female sex, n (%)
Race, n (%)
White
Nonwhite
Hydronephrosis, n (%)
History of UTI, n (%)
Stone size≥ 2 cm, n (%)
Level of access, n (%)
Below 12th rib
Between 11th and 12th ribs
Above 11th rib
No. of access sites (%)
1
2
Operative time (min), median (IQR)
EBL (mL), median (IQR)

7 Days (n=27)
57.0 (18.5)
32.3 (16.5)
21.0 (7.0)
17 (63.0)

Days of preoperative antibiotics
2 Days (n=39)
0 Days (n=72)
62.0 (20.5)
60.5 (17.0)
29.0 (10.9)
32.0 (8.3)
20.0 (6.5)
21.5 (13.0)
22 (56.4)
33 (45.8)

24 (88.9)
3 (11.1)
9 (33.3)
13 (48.1)
23 (85.2)

34 (87.2)
5 (12.8)
15 (38.5)
16 (41.0)
29 (74.4)

66 (91.7)
6 (8.3)
33 (45.8)
35 (48.6)
51 (70.8)

10 (37.0)
16 (59.3)
1 (3.8)

13 (33.3)
25 (64.1)
1 (2.6)

24 (33.3)
41 (57.0)
7 (9.7)

23 (85.2)
4 (14.8)
124.0 (75.0)
20.0 (67.5)

33 (84.6)
6 (15.4)
145.0 (81.5)
0.0 (52.5)

69 (95.7)
3 (4.3)
100.0 (45.5)
15.0 (25.0)

p-value
0.778
0.270
0.882
0.259
0.743

0.485
0.731
0.361
0.763

0.075

<0.001
0.564

IQR, interquartile range; BMI, body mass index; UTI, urinary tract infection; EBL, estimated blood loss.
Table 2. Signs of SIRS after percutaneous nephrolithotomy in patients receiving different durations of preoperative antibiotics
Variable
o

o

Temperature ≥38 C or ≤36 C
Heart rate >100 beats/min
Respiratory rate >20 breaths/min
White blood cell count >12,000/µL or <4,000/µL
Met SIRS criteria

7 Days (n=27)
1 (3.7)
2 (7.4)
0 (0)
5 (18.5)
1 (3.7)

Duration of antibiotics
2 Days (n=39)
0 (0)
3 (7.7)
0 (0)
2 (5.1)
2 (5.1)

0 Days (n=72)
1 (1.4)
4 (5.6)
0 (0)
2 (2.8)
3 (4.2)

p-value
0.433
0.816
0.022*
~1

Values are presented as number (%).
SIRS, systemic inflammatory response syndrome.
*p<0.05, statistically significant.
Investig Clin Urol 2016;57:417-423.
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abx, antibiotics; UTI, urinary tract infection; T, temperature; HR, heart rate; RR, respiratory rate; WBC, white blood cell count; ICU, intensive care unit admission; LOS, length of stay; cx, culture; NT,
nephrostomy tube; EBL, estimated blood loss; OR, operating room; Y, yes; N, no; NA, not available; Neg, negative; B12, below the 12th rib; A12, above the 12th, but below the 11th rib; A11, above the
11th rib; Coag-neg staph, Coagulase-negative staphylococci; sm, small or minimal.

N
N
N
N
Y
Y
20
24
25
90
29
51
M
F
M
2
2
7
4
5
6

Y
Y
N

N
Y
N

T ≥38oC HR >100
WBC
OR
RR >20 /
Secondary
# access Access
EBL
or
beats/
>12,000/µL Sepsis ICU LOS
Preop abx
Urine cx Blood cx
NT
time
min
procedure
tracts
site
(mL)
≤36oC
min
or <4,000/µL
(min)
P. aeruginosa
NA
1
B12
Y
25 119
N
Y
N
Y
N
N 7
NA
Cefazolin
N
Y
Y
Y
N
Y 8
NA
Cefazolin
Neg
Neg
1
A12
Y 100
80
Y
Y
N
Y
N
N 2
PCNL Piperacillin/
NA
NA
1
A11
Y sm 127
tazobactam
N
Y
Y
Y
N
Y 2
NA
Cefazolin
S. epidermidis
NA
1
B12
Y 250 309
N
Y
Y
Y
N
N 2
URS
Meropenem
NA
Neg
1
B12
Y
20 157
Y
Y
N
Y
Y
N 4
URS
Ciprofloxacin
NA
Coag-neg
1
B12
Y sm
80
staph

PCNL is generally safe and effective for the treatment
of large renal calculi and is considered first-line treatment
for staghorn stones [9,15-17]. While the risk of development
of any postoperative UTI is relatively high (e.g., fever and
bacteriuria develop in 21%–74% and 10%–37%, respectively)
[6-8], the risk of a severe infectious complication (i.e., sepsis),
is low (0.2%–4.7%) [15,18]. Thus, trepidation exists regarding
extended perioperative antibiotic use for PCNL, as the
sequelae of post-PCNL sepsis can be calamitous [4,5]. While
recent work has established that single-dose antibiotic
coverage is adequate for low-risk patients with sterile
preoperative urine [6], little is known about preoperative
antibiotic prophylaxis in high-risk patients. In the present
study, no dif ference in occurrence of SIRS was found
between high-risk patients who received 7, 2, or 0 days of
preoperative antibiotics (p=~1).
Infectious complications following PCNL can occur
despite sterile preoperative urine culture, making prevention
of these complications dif ficult. Additionally, treating

HydroUTI
nephrosis

DISCUSSION

Stone
Days
Patient
Sex Age size
of abx
(mm)
1
0
F 81
65
2
0
M 66
25
3
0
F 51
25

the groups, the number of patients with WBC>12,000/
µL or <4,000/µL was significantly higher for the 7 days
of antibiotics group (18.5%, vs. 5.1% for 2 days, and 2.8%
for 0 days, p=0.02). Two patients required postoperative
intensive care unit admission. Urine or blood culture data
was available for 5 of 6 patients with SIRS. Table 3 reports
the clinical and operative data for each of the patients with
SIRS.
In the 7- and 2-day groups, 50 patients (75.7%) received
oral ciprofloxacin as their preoperative antibiotic. The
remainder of patients received antibiotics tailored to their
history of prior positive cultures. Percutaneous access was
supracostal in 85 patients (61.6%) and subcostal in 53 patients
(38.4%). Mean operative time and blood loss were 127.2±57.4
minutes and 38.1±79.1 mL, respectively. Table 1 details the
operative data for the groups that received 7, 2, and 0 days
of preoperative antibiotic. There was a significant difference
in operative time, with those in the group that received 0
days of antibiotics having a shorter time (p<0.001). Median
length of stay was 1 day (range, 1–14 days). Nine patients
required a second-look PCNL for residual stone burden. Six
patients had a Clavien-Dindo grade II complication manifest
by hemorrhage requiring transf usion. Four patients
had Clavien-Dindo grade IIIa complications, including
pneumothorax (2), hydrothorax (1), and hemothorax (1).
Pneumothorax, hydrothorax, and hemothorax were managed
with temporary chest tube drainage.

Table 3. Clinical and operative data of patients with systemic inflammatory response syndrome

Potretzke et al
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positive preoperative urine cultures does not eliminate the
risk of postoperative SIRS [19]. Previous studies regarding
antibiotic prophylaxis for PCNL have suggested that
extended prophylactic antibiotic therapy prior to the day of
surgery may, in fact, reduce the risk of SIRS and infectious
complications in high-risk patients with sterile urine. Bag
et al. [20] randomized patients to 7 days of prophylaxis
with nitrofurantoin versus standard prophylaxis prior to
PCNL and noted a reduction in infectious complications:
19% vs. 49%, respectively. Similarly, Mariappan et al. [12]
prospectively evaluated 2 groups of high-risk patients
undergoing PCNL: those who received 7 days of ciprofloxacin
versus those who received standard prophylaxis. The
authors also noted a reduction in the incidence of SIRS.
The risk of SIRS for those receiving single-dose prophylaxis
was approximately 3 times that of those receiving extended
prophylaxis (relative risk, 2.9; 95% confidence interval, 1.3–6.3,
p=0.004). Despite these findings, the topic of proper antibiotic
prophylaxis in high-risk patients undergoing PCNL
continues to debated, as evidenced by the Best Practice
Statement put forth by the AUA.
The results of the present study conflict with those of
the prospective work by Mariappan et al. [12] and Bag et al.
[20]. One major difference in our series was the rate of SIRS:
3.7%, 5.1%, and 4.2% in those receiving 7, 2, and 0 days of
preoperative antibiotics, whereas Mariappan et al. [12] found
rates of SIRS to be 13.5% and 39.1% in the treatment and
control arms, respectively. Much of this difference may be
attributed to an ascertainment bias, given the retrospective
nature of the present study. Furthermore, more complete
stone culture data may have been illustrative and would be
important in future, prospective studies. Variability in SIRS
rates could be validated by differences in positive stone
culture rates, as stone cultures are more closely related to
the development of sepsis than urine culture alone [20,21].
Previously reported rates of SIRS after PCNL demon
strate a wide range: 9.8%–56.7% [21,22]. This variability
may be attributed to several causes. First, those studies
employing prospective, standardized protocols may be
more likely to detect clinical signs of SIRS, as opposed to
retrospective designs. Second, the criteria for inclusion varies
amongst PCNL studies, with some studies excluding highrisk patients, those with worrisome findings at the time of
access, and those with positive preoperative urine cultures.
The definition of SIRS has also been inconsistent across
studies. Further, the antibiotic regimens both pre- and
postoperatively have differed in the literature. Although
the rates presented herein appear to be lower than those
in previous manuscripts, Dogan et al. [23] reported a similar
Investig Clin Urol 2016;57:417-423.

rate of 1.5% in 338 patients.
While the present study investigates the use of pre
operative antibiotics, others have evaluated the need for
prophylactic antibiotic coverage after PCNL. Recent work by
Deshmukh et al. [24] showed that adherence to the AUA’s
Best Practice recommendations of a single, preoperative
dose did not result in a higher post-PCNL infection rate
compared to those who received ~6 days of postoperative
antibiotics. Similarly, Dogan et al. [25] found no difference in
rates of post-PCNL fever in patients who received a single
preoperative dose versus a postoperative course extending
to nephrostomy tube removal. Seyrek et al. [22] prospectively
randomized 198 patients to receive a single postoperative
dose, an additional dose at 12 hours post-PCNL, or antibiotics
until the time of nephrostomy tube removal. The authors
found no difference in rates of SIRS between the groups.
Tuzel et al. [26] reported on 73 patients randomized to
a single preoperative dose or a regimen to be extended
postoperatively until the time of nephrostomy tube removal.
They found no difference in either fever or septicemia.
Owing to the potential for severe infectious complications,
the anecdotal and surgeon-specific use of an extended
course of antibiotics is understandable. Evidence continues
to emerge, however, supporting the use of short-course or
single intraoperative doses of antibiotics. Moreover, both the
AUA and EAU have recommended such prophylaxis. The
potential overuse of antibiotics, and the associated increase
in highly-resistant organisms, is of paramount concern.
Antibiotic stewardship will be vital to the future effective
prevention and treatment of UTIs. Cai et al. [27] reported
their experience of antibiotic use, infection, and prevalence
of drug-resistant uropathogens by comparing 2,619 and
3,529 patients who underwent a urologic procedure before
and after the implementation of an antibiotic protocol that
was consistent with the EAU’s guidelines. During the study
period they found a similar rate of infections. There was also
a significant decrease in use of antibiotics, decreased cost,
and decreased rates of resistance to antibiotics (ciprofloxacin,
piperacillin-tazobactam, and gentamicin).
The present study has limitations. First, it is a retro
spective review of a single-center experience. Certainly
biases such as patient selection for PCNL could be manifest.
Furthermore, due to the retrospective collection of data, the
availability of postoperative antibiotic administration and
complete blood, urine, and stone culture data in each patient
is lacking. The clinical outcome of sepsis could not be studied
in the present work due to the lack of uniform blood culture
data. Ideally, in future prospective studies, blood cultures
would be obtained in any patient who meets one SIRS
www.icurology.org
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criterion, while urine and stone cultures would be obtained
in all patients postoperatively. Differences in the culture
collection practices were surgeon-specific; the difference
between surgeons also explains the significant difference
in operative times (the surgeon for the group that received
zero of preoperative antibiotics group had significantly
lower operative times than the other surgeon, p<0.001).
Additionally, the small number of patients who developed
SIRS limits the ability to perform f urther statistical
evaluations such as a multivariate analysis designed to
identify predictors of SIRS after PCNL. Also, during the
study period, the specific antibiotic was not standardized
amongst surgeons, although selection was based on either
AUA guidelines or previous positive culture sensitivities.
Finally, the use of the terms SIRS and sepsis have become
more precise in recent years and are now well-defined [28].
We chose to employ the definition used by Mariappan et al.
[12] for simplicity and comparability.
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